Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

SAN DIEGO, Nov. 7, 2013 /PRNewswire/ -- Ambit Biosciences (NASDAQ: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced third quarter and year-to-date operating results for 2013.  The company will host a conference call today to discuss financial results for the third quarter and year-to-date, and to provide an operational update on developments in the quarter.

"We are pleased to have made good progress toward our goals during the third quarter, moving forward in the development of our lead drug candidate, quizartinib.  We are excited about the upcoming events at ASH in December, where we will have the opportunity to present data from our most recent studies," said Michael Martino, Ambit's president and Chief Executive Officer. "As we head into the last quarter of 2013, we are looking forward to feedback from our upcoming FDA meeting in November and we will provide an update on our development and regulatory plans for quizartinib following that meeting.  Additionally, we remain on track to start our Phase 3 trial in early-2014, as previously guided."

Operational Update
The Company is pleased to announce the acceptance of four abstracts with preliminary data highlighting the Company's lead drug candidate, quizartinib.  Presentations of the final data and two additional posters will be presented during the ASH 55th Annual Meeting at the Ernest Morial Convention Center in New Orleans, LA on December 9, 2013.  Oral presentations include the following:

Results of Phase 2 Randomized, Open-Label, Study of Lower Doses of Quizartinib in Subjects with FLT3-ITD Positive Relapsed Acute Myeloid Leukemia (AML):  The purpo
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 23, 2014 According to Ross ... Island Affiliate of ITRA Global, the national office market continues ... recovery. This is evidenced by the third quarter’s surprising ... market. Low energy costs have held inflation down and ... negative is the housing market remaining soft. , This solid ...
(Date:12/24/2014)... 23, 2014 China Biologic Products, Inc. ... leading fully integrated plasma-based biopharmaceutical company in ... majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., ... the China Food and Drug Administration (the "CFDA") ... previously disclosed in the Company,s public filings, the ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 ... pilot study of mazindol in children with attention deficit/hyperactivity ... in December 2014 . The paper, ... with attention deficit/hyperactivity disorder" ( Konofal et al, ... 1;8:2321-2332. eCollection 2014 ) shows that mazindol might ...
(Date:12/22/2014)... DIEGO , Dec. 22, 2014 GenomeDx ... the Decipher Prostate Cancer Classifier, a genomic test for ... in node-negative, high-risk men managed by radical prostatectomy without ... radical prostatectomy is relatively uncommon, using tumor genomics to ... of metastatic disease is an important advance. The study ...
Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3
... , , , , from marine bacterium BMTU , ... , Catalog Number, Pack Size, ... 100 units, , , ... , , , , , , Package Inserts/Product , Instructions , ...
... , , , , , ... , 1691112, 100 g, , ... Instructions , , German , ... , , US Material Safety , Data Sheets, , ...
... , , , Catalog Number, ... 1636138, 1 kit, , , ... , , English , version - 41 ... , US Material Safety , Data Sheets , ...
Cached Biology Technology:
(Date:12/10/2014)... RALEIGH, N.C. , Dec. 9, 2014  Valencell, ... announced it is seeing a staggering demand from its ... demand, the Company revealed, is not solely coming from ... industries as well. "A wearable is only ... a result, accuracy is the ultimate driver in long-term ...
(Date:12/10/2014)... California , December 9, 2014 ... with ITN,s BCARD Platform   ... cloud-based enterprise meeting scheduling solutions for business-to-business (B2B) ... the world leader in mobile near-field communication (NFC), ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , ...
(Date:12/3/2014)... Dec. 2, 2014   Marvin Test Solutions ... test solutions for military, aerospace, and manufacturing organizations, ... its successful TS-900 PXI semiconductor test platform ... of high-end systems to customers at a fraction ... to traditional ATE. "Our semiconductor ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... SUNNYVALE, Calif., July 14 Fujitsu Computer ... computer products including hard disk drives, peripherals and biometric ... PalmSecure vascular biometric authentication technology has been ... Security Evaluation as Evaluation Assurance Level 2. PalmSecure is ...
... -- The stress of rising natural gas prices is leading ... For some this means moving towards modern alternative energy options, ... for a solution to these rising costs. In Canada ... as a potentially viable option for home heating. , ...
... of unicellular marine microorganisms that are not only a crucial ... fossils, which are found in abundance, provide scientists with an ... the history of the earth. Now, planktonic foraminifera ... have given up a secret of their very own. ...
Cached Biology News:Fujitsu PalmSecure Certified Under International Common Criteria Evaluation Assurance Level 2 2Fujitsu PalmSecure Certified Under International Common Criteria Evaluation Assurance Level 2 3Wood stoves -- a viable home heat source? 2Surviving mass extinction by leading a double life 2
... Peptide sequences: Two separate ... corresponding to the same sequence used ... antiserum (Catalog No. 160890) ... with Cayman's guanylate cyclase polyclonal antiserum ...
Immunogen: Secretory component isolated from human colostrum. Storage: 4 C...
Negative Control, eluted and packaged aseptically in 20l of 10mM Tris-HCL, pH 8.0, 1 mM EDTA, 5 years at either 4°C or -20°C...
AdestaTM Tissue/Cell Preservation Medium Sterile / Non-sterile: Sterility Tested Endotoxin: ...
Biology Products: